The mevalonate pathway results in the prenylation of small GTPases, which are pivotal for oncogenesis and cancer malignancies. However, inhibitors of this pathway, such as statins, have not necessarily produced favorable results in clinical trials. We recently identified properties of statin responders, together with the underlying molecular mechanisms and simple biomarkers to predict these responders.
CITATION STYLE
Sabe, H., Hashimoto, A., Hashimoto, S., & Oikawa, T. (2016, July 3). Tumor responsiveness to statins requires overexpression of the ARF6 pathway. Molecular and Cellular Oncology. Taylor and Francis Ltd. https://doi.org/10.1080/23723556.2016.1185564
Mendeley helps you to discover research relevant for your work.